Eli Lilly To Utilize Lycia's LYTAC Platform To Treat Challenging Disease Areas

Eli Lilly and Company (LLY) has entered into a research collaboration and licensing agreement with Lycia Therapeutics to address key unmet medical needs in Lilly's therapeutic areas of focus, including immunology and pain. Headquartered in South San Francisco, Lycia is a biotechnology company using its lysosomal targeting chimeras (LYTACs) platform to develop therapeutics that degrade proteins that drive a range of diseases, including cancers and autoimmune conditions.